Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Down-regulation of SARS-CoV-2 neutralizing antibodies in vaccinated smokers

Jiahui Zhang, Fei Teng, Xiaomei Zhang, Hongye Wang, Te Liang, Shubin Guo, View ORCID ProfileXiaobo Yu
doi: https://doi.org/10.1101/2021.12.09.21267349
Jiahui Zhang
1State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fei Teng
2Emergency Medicine Clinical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, & Beijing Key Laboratory of Cardiopulmonary Cerebral Resuscitation, Beijing, 100020, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaomei Zhang
1State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hongye Wang
1State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Te Liang
1State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shubin Guo
2Emergency Medicine Clinical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, & Beijing Key Laboratory of Cardiopulmonary Cerebral Resuscitation, Beijing, 100020, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yuxiaobo@ncpsb.org.cn shubinguo@126.com
Xiaobo Yu
1State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Xiaobo Yu
  • For correspondence: yuxiaobo@ncpsb.org.cn shubinguo@126.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Vaccination is an effective approach to help control coronavirus disease 2019 (COVID-19). However, since the vaccines produce a heterogenous immune response, the risk of breakthrough infection is increased in vaccinated individuals who generate low levels of neutralizing antibodies (NAbs). It is therefore paramount in the fight against COVID-19 to identify individuals who have a higher risk of breakthrough infection despite being vaccinated. Here we addressed the effect of cigarette smoking on the production of neutralizing antibodies (NAbs) following COVID-19 vaccination since smoking profoundly suppresses the adaptive immune response to pathogen infection and the association between vaccination and smoking remains unclear. The SARS-CoV-2 Spike antibodies and NAbs (days 0, 14, 42, and 90) were measured in 164 participants received two vaccine doses of an inactivated vaccine (Sinovac-CoronaVac) longitudinally. Anti-Spike antibodies was elevated 14 and 42 days after COVID-19 vaccination compared to baseline (i.e., “Day 0”). Notably, RBD antibodies showed significantly higher expression in the nonsmoking group (n=153) than the smoking (n=11) group on day 42 (p<0.0001, Student’s t-test). NAbs continually increased after the first and second vaccine dose, peaking on day 42. NAbs titers then significantly decreased until day 90. Compared to nonsmokers, the NAb levels in smokers remained low throughout the period of testing. The median NAb titers in the smoking group was 1.40-, 1.32-, or 3.00-fold lower than that of nonsmoking group on day 14, 42, or 90, respectively. Altogether, our results indicate that smoking is a specific risk factor for COVID-19 breakthrough infection following vaccination.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study is supported by grants from the National Key R&D Program of China (2020YFE0202200), Beijing Municipal Education Commission (COVID-19 Emergency Response Project in Beijing Universities), Beijing Municipal Natural Science Foundation (M21003) and Beijing Municipal Science & Technology Commission (Z211102002520000), State Key Laboratory of Proteomics (SKLP-C202001, SKLP-O201904).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee/IRB of Beijing Chaoyang Hospital gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted December 11, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Down-regulation of SARS-CoV-2 neutralizing antibodies in vaccinated smokers
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Down-regulation of SARS-CoV-2 neutralizing antibodies in vaccinated smokers
Jiahui Zhang, Fei Teng, Xiaomei Zhang, Hongye Wang, Te Liang, Shubin Guo, Xiaobo Yu
medRxiv 2021.12.09.21267349; doi: https://doi.org/10.1101/2021.12.09.21267349
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Down-regulation of SARS-CoV-2 neutralizing antibodies in vaccinated smokers
Jiahui Zhang, Fei Teng, Xiaomei Zhang, Hongye Wang, Te Liang, Shubin Guo, Xiaobo Yu
medRxiv 2021.12.09.21267349; doi: https://doi.org/10.1101/2021.12.09.21267349

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (161)
  • Allergy and Immunology (414)
  • Anesthesia (90)
  • Cardiovascular Medicine (858)
  • Dentistry and Oral Medicine (159)
  • Dermatology (97)
  • Emergency Medicine (248)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
  • Epidemiology (8561)
  • Forensic Medicine (4)
  • Gastroenterology (383)
  • Genetic and Genomic Medicine (1749)
  • Geriatric Medicine (167)
  • Health Economics (372)
  • Health Informatics (1242)
  • Health Policy (620)
  • Health Systems and Quality Improvement (467)
  • Hematology (196)
  • HIV/AIDS (372)
  • Infectious Diseases (except HIV/AIDS) (10299)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (211)
  • Neurology (1677)
  • Nursing (97)
  • Nutrition (251)
  • Obstetrics and Gynecology (326)
  • Occupational and Environmental Health (450)
  • Oncology (928)
  • Ophthalmology (263)
  • Orthopedics (102)
  • Otolaryngology (172)
  • Pain Medicine (113)
  • Palliative Medicine (40)
  • Pathology (253)
  • Pediatrics (534)
  • Pharmacology and Therapeutics (252)
  • Primary Care Research (208)
  • Psychiatry and Clinical Psychology (1768)
  • Public and Global Health (3837)
  • Radiology and Imaging (623)
  • Rehabilitation Medicine and Physical Therapy (320)
  • Respiratory Medicine (520)
  • Rheumatology (208)
  • Sexual and Reproductive Health (167)
  • Sports Medicine (158)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)